About Angle plc
ANGLE plc: Revolutionizing Cancer Research with Innovative Solutions
ANGLE plc is a leading biotechnology company that specializes in developing innovative solutions for translational researchers. The company's primary focus is on capturing and harvesting circulating tumor cells (CTCs) and other rare cells of interest, which can provide valuable insights into cancer diagnosis, prognosis, and treatment.
With over a decade of experience in the field of cancer research, ANGLE has established itself as a trusted partner for academic institutions, pharmaceutical companies, and clinical research organizations worldwide. The company's flagship product, the Parsortix system, is a revolutionary liquid biopsy technology that enables non-invasive detection and analysis of CTCs from patient blood samples.
The Parsortix system uses microfluidic technology to isolate CTCs based on their size and deformability. This approach offers several advantages over traditional methods such as immunomagnetic separation or fluorescence-activated cell sorting (FACS). Firstly, it allows for the capture of intact CTCs without damaging them or altering their phenotype. Secondly, it enables the isolation of rare subpopulations of CTCs that may be missed by other methods due to their low abundance or heterogeneity.
The Parsortix system has been validated in numerous clinical studies across different cancer types such as breast cancer, prostate cancer, lung cancer, ovarian cancer etc., demonstrating its potential as a powerful tool for personalized medicine. By analyzing CTCs from patient blood samples using the Parsortix system researchers can gain insights into tumor biology such as genetic mutations or drug resistance mechanisms which can help guide treatment decisions.
In addition to its flagship product Parsortix ANGLE also offers complementary services such as sample processing kits and analytical services to support translational research projects. The company has established collaborations with leading academic institutions like MD Anderson Cancer Center in Texas USA , University Medical Center Hamburg-Eppendorf Germany , University Hospital Basel Switzerland etc., to advance our understanding of how liquid biopsy technologies like Parsortix can improve patient outcomes.
ANGLE's commitment to innovation extends beyond its products; the company invests heavily in R&D activities aimed at improving existing technologies or developing new ones altogether. For example recently they have developed an Epithelial-Mesenchymal Transition (EMT) liquid biopsy assay which detects EMT status within captured circulating tumor cells (CTCs). This assay provides additional information about metastatic potential beyond just enumeration alone.
In conclusion ANGLE plc is an innovative biotechnology company that is revolutionizing how we approach translational research in oncology through its cutting-edge liquid biopsy technology -the Parsortix System . With its commitment to innovation excellence customer service quality assurance regulatory compliance ethical standards environmental responsibility social responsibility employee development community involvement etc., ANGLE sets itself apart from competitors by providing exceptional value-added solutions tailored specifically towards meeting customer needs while maintaining high standards across all aspects of business operations .